Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
54.23 USD +1.84% Intraday chart for Bristol-Myers Squibb Company +4.53% +5.69%

Evolution of the average Target Price on Bristol-Myers Squibb Company

Price target over the last 5 years

History of analyst recommendation changes

7d678d0.xohli7822Uq2OvzF8QO9Ca6ss3fTAqnOwwvfdt9PsVA.gcon4NFElHjdbMmLpkTLZvfVhQGKVMqHgEa4DKoB_jmF_Va_zlCYKcMIqQ~10d35372b9424f1f5deb6c09db618c10
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85 MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77 MT
That's good enough for investors Our Logo
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla... Our Logo
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024 MT
BofA Securities Downgrades Bristol-Myers Squibb to Neutral From Buy, Price Target is $60 MT
Morgan Stanley Cuts Price Target on Bristol-Myers Squibb to $42 From $50, Keeps Underweight Rating MT
Are rate cuts are coming early next year? Our Logo
Joe Biden and Xi Jinping almost made up Our Logo
Cantor Fitzgerald Downgrades Bristol-Myers Squibb to Neutral From Overweight, Cuts Price Target to $55 From $68 MT
Deutsche Bank Initiates Coverage on Bristol-Myers Squibb With Hold Rating, $55 Price Target MT
Daiwa Securities Downgrades Bristol-Myers Squibb to Neutral From Outperform, Adjusts Price Target to $54 From $68 MT
Berenberg Bank Adjusts Bristol-Myers Squibb Price Target to $60 From $76, Maintains Hold Rating MT
Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating MT
North American Morning Briefing : Rate Decisions, -2- DJ
UBS Adjusts Bristol-Myers Squibb Price Target to $57 From $60, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $51 From $60, Maintains Equal-Weight Rating MT
William Blair Downgrades Bristol-Myers Squibb to Market Perform From Outperform MT
BMO Capital Downgrades Bristol-Myers Squibb to Market Perform From Outperform, Cuts Price Target to $60 From $70 MT
HSBC Upgrades Bristol-Myers Squibb to Hold From Reduce, Cuts Price Target to $53 From $55 MT
Morgan Stanley Cuts Price Target on Bristol-Myers Squibb to $50 From $56, Says Lower Medium-Term Guidance Raises Questions on 2030 Targets, Keeps Underweight Rating MT
ANALYST RECOMMENDATIONS : Amazon, Comcast, Intel, Merck, Roblox... Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
53.25 USD
Average target price
56.41 USD
Spread / Average Target
+5.94%
High Price Target
75 USD
Spread / Highest target
+40.85%
Low Price Target
41 USD
Spread / Lowest Target
-23.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bristol-Myers Squibb Company

Societe Generale
Wells Fargo Securities
Redburn
Morgan Stanley
UBS
BofA Securities
Cantor Fitzgerald
Deutsche Bank Securities
Daiwa Securities
Berenberg Bank
Goldman Sachs
William Blair & Co.
Barclays
BMO Capital
HSBC
TD Cowen
Jefferies & Co.
Credit Suisse
Atlantic Equities
Guggenheim
JPMorgan Chase
Raymond James
Citigroup
Truist Securities
Argus
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. Consensus Bristol-Myers Squibb Company